colitis, hepatic fibrosis, and viral infections such as HBV, HCV, HPV, RSV, SARS, HIV, or influenza.

SUMMARY ~~OF THE INVENTION~~

In accordance with the foregoing, ~~in one aspect the present invention provides~~disclosed are compounds of Formula I:



I

or pharmaceutically acceptable salts thereof, wherein:

L^1 is $-NR^8-$, -O-, -S-, $-N(R^8)C(O)-$, $-S(O)_2-$, -S(O)-, or a covalent bond;

R^1 is H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, substituted heterocyclylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylalkenyl, substituted carbocyclylalkenyl, carbocyclylalkynyl, substituted carbocyclylalkynyl, heterocyclylalkenyl, substituted heterocyclylalkenyl, heterocyclylalkynyl, substituted heterocycloalkynyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroarylalkenyl, substituted heteroarylalkenyl, heteroarylalkynyl, substituted heteroarylalkynyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl, heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl;

X^2 is N or $C-R^5$;

R^5 is H, halogen, alkyl, substituted alkyl, haloalkyl, alkoxy, substituted alkoxy, haloalkoxy, aminoalkyl, substituted aminoalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted

heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted heterocyclylalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylalkenyl, substituted carbocyclylalkenyl, carbocyclylalkynyl, substituted carbocyclylalkynyl, heterocyclylalkenyl, substituted heterocyclylalkenyl, heterocyclylalkynyl, substituted heterocyclylalkynyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroarylalkenyl, substituted heteroarylalkenyl, heteroarylalkynyl, substituted heteroarylalkynyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl, heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl; or

R^9 and R^{10}, taken together with the atom to which they are both attached, form a substituted or unsubstituted 3 to 8 membered heterocycle, which may contain one or more additional heteroatoms selected from N, O, S, or P.

In one aspect, there is provided a compound of Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

L^1 is -O-;

R^1 is H, C_{1-6} alkyl, C_{1-6} heteroalkyl, or C_{4-20} heterocyclylalkyl, wherein each heteroalkyl group includes 1 or 2 heteroatoms selected from O, N, or S, and wherein each heterocyclyl group includes 1 to 6 heteroatoms selected from O, N, or S;

X^2 is N or C-R^5;

R^5 is H, halogen, or C_{1-6} alkyl;

X^1 is C_{1-6} alkylene;

D^1 is phenyl, pyridinyl or thiazolyl;

D^2 is phenyl, pyridinyl or thiazolyl;

each L^2 is independently C_{1-6} alkylene;

each R^2 is independently $-NR^6R^7$;

m is 1;

each R^3 and R^4 is independently halogen, C_{1-6} haloalkyl, $-OR^8$, or -CN;

each n is independently 0, 1, 2, 3, or 4, depending on the size of the depicted ring D^1 and D^2, such that sufficient attachment points are present for each R^3 and R^4;

R^6 and R^7 are each independently H, or C_{1-6} alkyl; or

R^6 and R^7, taken together with the nitrogen to which they are both attached, form a substituted or unsubstituted 3 to 8 membered heterocycle, which may contain one or more additional heteroatoms selected from N, O, S, or P; or

R^7 taken together with L^2, and the N to which they are both attached, forms a substituted or unsubstituted 3 to 8 membered heterocycle which may contain one or more additional heteroatoms selected from N, O, S, or P; or

R^7 taken together with D^2, L^2, and the N to which both R^7 and L^2 are attached forms a substituted or unsubstitued 5 to 15 membered heterocycle or heteroaryl which may contain one or more additional heteroatoms selected from N, O, S, or P; and

R^8 is H, or C_{1-6} alkyl.

In another aspect, there is provided a compound selected from the group consisting of:

















































X





































































, and



or a pharmaceutically acceptable salt thereof.

In another aspect, there is provided a pharmaceutical composition comprising a compound described herein, and one or more pharmaceutically acceptable carrier or excipient.

~~Another aspect of the present invention includes~~ Disclosed is a compound of the present ~~invention~~ disclosure and one or more pharmaceutically acceptable carrier or excipient. In a further embodiment, the composition further comprises one or more additional therapeutic agent.

~~Another aspect of the present invention includes~~ Disclosed is a compound of the present disclosure~~invention~~ in a method for treating a viral infection. In one embodiment, the treatment results in one or more of a reduction in viral load or clearance of viral RNA.

In another aspect, there is provided a use of a compound described herein for the manufacture of a medicament for the treatment of a viral infection.

~~Another aspect of the present invention includes~~Disclosed is a compound of the present ~~invention~~ disclosure for use in the manufacture of a medicament for the treatment of a viral infection.

In another aspect, there is provided a compound described herein for the use in treating a viral infection.

~~Another aspect of the present invention includes~~Disclosed is a compound of the present ~~invention~~disclosure for the use in treating a viral infection.

In one embodiment, either such use or compound for treatment results in one or more of a reduction in viral load or clearance of RNA.

In another aspect, there is provided use of a compound described herein for the manufacture of a medicament for the treatment or prevention of melanoma, non-small cell lung

carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, or influenza.

~~Another aspect of the present invention includes~~Disclosed is a compound of the present ~~invention~~ disclosure in a method for treating or preventing melanoma, non-small cell lung carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, or influenza.

~~Another aspect of the present invention includes~~Disclosed is a compound of the present ~~invention~~disclosure for use in the manufacture of a medicament for the treatment or prevention of melanoma, non-small cell lung carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, or influenza.

While not wishing to be bound by theory, the inventors currently believe that the compounds of Formula I are agonists of TLR-7 and may also be agonists of other TLRs. Thus, compounds of the present disclosure~~invention~~ can be used to treat or prevent diseases for which modulators of TLRs, and in particular TLR-7, exert a therapeutic effect. For example, such diseases include melanoma, non-small cell lung carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, and influenza.

~~As noted an aspect of the present invention includes~~Disclosed is a pharmaceutical composition comprising a compound of the present disclosure~~invention~~ and one or more pharmaceutically acceptable carrier or excipient. The pharmaceutical composition of the present disclosure~~invention~~ may further comprise one or more additional therapeutic agent. The one or more additional therapeutic agent may be, without limitation, selected from: interferons, ribavirin or its analogs, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, nucleoside or nucleotide inhibitors of HCV NS5B polymerase, non-nucleoside inhibitors of HCV NS5B polymerase, HCV NS5A inhibitors, HCV NS4A inhibitors, HCV NS4B inhibitors, TLR-7 agonists, cyclophillin inhibitors, HCV IRES inhibitors, pharmacokinetic enhancers, and other drugs for treating HCV, or mixtures thereof.

~~As noted, an aspect of the present invention includes~~ Disclosed is a method for treating a viral infection comprising administering a compound of the present ~~invention~~disclosure. The compound is administered to a human subject in need thereof, such as a human being who is infected with a virus of the Flaviviridae family, such as hepatitis C virus. In one embodiment, the viral infection is acute or chronic HCV infection. In one embodiment, the treatment results in one or more of a reduction in viral load or clearance of RNA. As noted hereinabove, there are a number of diseases, disorders, and conditions linked to TLRs such that therapies using a TLR agonist are believed promising, including but not limited to melanoma, non-small cell lung carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, and viral infections such as HBV, HCV, HPV, RSV, SARS, HIV, or influenza

~~As noted, an aspect of the present invention includes~~Disclosed is the use of a compound according to the present disclosure~~invention~~ for the manufacture of a medicament for the treatment of a viral infection. ~~Another aspect of the present invention includes~~Disclosed is a compound according to the present disclosure~~invention~~ for the use in treating a viral infection. In one

embodiment, the viral infection is acute or chronic HCV infection. In one embodiment, the treatment results in one or more of a reduction in viral load or clearance of RNA. In one embodiment, the viral infection is acute or chronic HBV infection. In one embodiment, the treatment results in one or more of a reduction in viral load or clearance of RNA.

The present disclosure~~invention~~ includes combinations of aspects and embodiments, as well as preferences, as herein described throughout the present specification.

DETAILED DESCRIPTION

Reference will now be made in detail to certain claims of the invention, examples of which are illustrated in the accompanying structures and formulas. While the invention will be described in conjunction with the enumerated claims, it will be understood that they are not intended to limit the invention to those claims. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims.

All documents referenced herein are each incorporated by reference in their entirety for all purposes.

Definitions

Unless stated otherwise, the following terms and phrases as used herein are intended to have the following meanings. The fact that a particular term or phrase is not specifically defined should not be correlated to indefiniteness or lacking clarity, but rather terms herein are used within their ordinary meaning. When trade names are used herein, applicants intend to independently include the tradename product and the active pharmaceutical ingredient(s) of the tradename product.

The term "treating", and grammatical equivalents thereof, when used in the context of treating a disease, means slowing or stopping the progression of a disease, or ameliorating at least one symptom of a disease, more preferably ameliorating more than one symptom of a disease. For example, treatment of a hepatitis C virus infection can include reducing the HCV viral load in an HCV infected human being, and/or reducing the severity of jaundice present in an HCV infected human being.

As used herein, "a compound of the invention" or "a compound of formula I" means a compound of formula I, including alternative forms thereof such as, solvated forms, hydrated forms, esterified forms, or physiologically functional derivatives thereof. Compounds of the invention also include tautomeric forms thereof, e.g., tautomeric "enols" as described herein. Similarly, with respect to isolatable intermediates, the phrase

WE CLAIM:

1. A compound of Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

L^1 is -O-;

R^1 is H, C_{1-6} alkyl, C_{1-6} heteroalkyl, or C_{4-20} heterocyclylalkyl, wherein each heteroalkyl group includes 1 or 2 heteroatoms selected from O, N, or S, and wherein each heterocyclyl group includes 1 to 6 heteroatoms selected from O, N, or S;

X^2 is N or C-R^5;

R^5 is H, halogen, or C_{1-6} alkyl;

X^1 is C_{1-6} alkylene;

D^1 is phenyl, pyridinyl or thiazolyl;

D^2 is phenyl, pyridinyl or thiazolyl;

each L^2 is independently C_{1-6} alkylene;

each R^2 is independently $-NR^6R^7$;

m is 1;

each R^3 and R^4 is independently halogen, C_{1-6} haloalkyl, $-OR^8$, or -CN;

each n is independently 0, 1, 2, 3, or 4, depending on the size of the depicted ring D^1 and D^2, such that sufficient attachment points are present for each R^3 and R^4;

R^6 and R^7 are each independently H, or C_{1-6} alkyl; or

R^6 and R^7, taken together with the nitrogen to which they are both attached, form a substituted or unsubstituted 3 to 8 membered heterocycle, which may contain one or more additional heteroatoms selected from N, O, S, or P ; or

R^7 taken together with L^2, and the N to which they are both attached, forms a substituted or unsubstituted 3 to 8 membered heterocycle which may contain one or more additional heteroatoms selected from N, O, S, or P ; or

R^7 taken together with D^2, L^2, and the N to which both R^7 and L^2 are attached forms a substituted or unsubstitued 5 to 15 membered heterocycle or heteroaryl which may contain one or more additional heteroatoms selected from N, O, S, or P ; and

R^8 is H, or C_{1-6} alkyl.

2. A compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein:
n is 0, 1, or 2.

3. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R^6 and R^7 together with the nitrogen to which they are attached form a substituted or unsubstituted 3 to 8 membered heterocyclyl, which may contain one or more additional heteroatoms selected from N, O, S, or P, wherein the substituted heterocycle is substituted with C_{1-6} alkyl.

4. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R^6 is H, or C_{1-6} alkyl; and
R^7 taken together with D^2, L^2, and the N to which both R^7 and L^2 are attached forms a substituted or unsubstitued 5 to 15 membered heterocycle or heteroaryl which may contain one or more additional heteroatoms selected from N, O, S, or P, wherein the substituted heterocycle is substituted with C_{1-6} alkyl.

5. The compound of any one of claims 1 - 4, wherein X^2 is N.

6. The compound of any one of claims 1 - 4, wherein X^2 is C-R^5.

7. The compound of any one of claims 1 - 6, wherein X^1 is C_{1-6} alkylene.

8. The compound of any one of claims 1-7, wherein D^1 is phenyl.

9. The compound of any one of claims 1 - 8, wherein D^2 is phenyl.

10. A compound selected from the group consisting of:


,

,

,

,

,

,

,

,



,



,



,



,



,



,


,


,


,


,


,


,



,



,



,



X

,



,



,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,


,



,



, and



,

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 10, having the formula:



or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound according to Claims 1 – 11, and one or more pharmaceutically acceptable carrier or excipient.

13. The pharmaceutical composition of Claim 12, further comprising one or more additional therapeutic agent.

14. Use of a compound according to Claims 1 – 11 for the manufacture of a medicament for the treatment of a viral infection.

15. A compound according to Claims 1 – 11 for the use in treating a viral infection.

16. The use or compound of Claim 14 or 15 wherein the treatment results in one or more of a reduction in viral load or clearance of viral RNA.

17. Use of a compound according to Claims 1 – 11 for the manufacture of a medicament for the treatment or prevention of melanoma, non-small cell lung carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, or influenza.

WE CLAIM:

1. A compound of Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

L^1 is $-NR^8-$, -O-, -S-, $-N(R^8)C(O)-$, $-S(O)_2-$, -S(O)-, or a covalent bond;

R^1 is H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, substituted heterocyclylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylalkenyl, substituted carbocyclylalkenyl, carbocyclylalkynyl, substituted carbocyclylalkynyl, heterocyclylalkenyl, substituted heterocyclylalkenyl, heterocyclylalkynyl, substituted heterocycloalkynyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroarylalkenyl, substituted heteroarylalkenyl, heteroarylalkynyl, substituted heteroarylalkynyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl, heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl;

X^2 is N or C-R^5;

R^5 is H, halogen, alkyl, substituted alkyl, haloalkyl, , alkoxy, substituted alkoxy, haloalkoxy, aminoalkyl, substituted aminoalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclylalkyl, substituted heterocyclylalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl,

heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl, cyano, azido, -C(O)H, -C(O)R^8, -S(O)R^8, -S(O)$_2R^8$, -S(O)$_2NR^8R^9$, -C(O)OR^8, or -C(O)NR^9R^{10};

each non-hydrogen R^5 may optionally connect to X^1 to form an additional 5 to 8 membered carbocyclic or heterocyclic ring;

each non-hydrogen R^5 may optionally connect to D^1 to form an additional 5 to 8 membered carbocyclic or heterocyclic ring;

X^1 is alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, carbocyclylene, substituted carbocyclylene, heterocyclylene, substituted heterocyclylene, -NR^6-, -O-, -C(O)-, -S(O)-, -S(O)$_2$-, or a covalent bond;

D^1 is aryl or heteroaryl;

D^2 is aryl or heteroaryl;

each L^2 is independently alkylene, substituted alkylene, heteroalkylene, substituted heteroalkylene, or a covalent bond;

each R^2 is independently –NR^6R^7;

m is 1 or 2;

each R^3 and R^4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, heteroalkyl, substituted heteroalkyl, =O, -OR^8, -SR^8, -NR^9R^{10}, =NR^8, =NOR^8, =NNR^8R^9, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, -NO$_2$, =N$_2$, -N$_3$, -NR^6C(=O)R^9, -NR^6C(=O)OR^9, -NR^8C(=O)NR^9R^{10}, -C(=O)NR^9R^{10}, -C(=O)OR^8, -OC(=O)NR^9R^{10}, -OC(=O)OR^8, -C(=O)R^8, -S(=O)$_2$OR^8, -S(=O)$_2R^8$, -OS(=O)$_2$OR^8, -S(=O)$_2NR^9R^{10}$, -S(=O)R^8, -NR^8S(=O)$_2R^9$, -NR^8S(=O)$_2NR^9R^{10}$, -NR^8S(=O)$_2$OR^9, -OS(O)$_2NR^9R^{10}$, -OP(=O)(OR^8)$_2$, -P(=O)(OR^8)$_2$, -P(O)(OR^8)(R^9), -P(O)R^9R^{10}, -OP(=O)R^9R^{10}, -C(=S)R^8, -C(=S)OR^8, -C(=O)SR^8, -C(=S)SR^8, -C(=S)NR^9R^{10}, -C(=NR^8)NR^9R^{10}, or -NR^8C(=NR^8)NR^9R^{10};

each n is independently 0, 1, 2, 3, 4 or 5, depending on the size of the depicted ring D^1 and D^2, such that sufficient attachment points are present for each R^3 and R^4;

R^6 and R^7 are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, haloalkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclylalkyl, substituted heterocyclylalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl,carbocyclylalkenyl, substituted carbocyclylalkenyl, carbocyclylalkynyl, substituted carbocyclylalkynyl, heterocyclylalkenyl,

substituted heterocyclylalkenyl, heterocyclylalkynyl, substituted heteroalkynyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroarylalkenyl, substituted heteroarylalkenyl, heteroarylalkynyl, substituted heteroarylalkynyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl, heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl, -C(O)H, -C(O)R^8, -S(O)R^8, -S(O)$_2R^8$, -C(O)OR^8, or -C(O)NR^9R^{10}, S(O)$_2$NR^9R^{10}; or

R^6 and R^7, taken together with the nitrogen to which they are both attached, form a substituted or unsubstituted 3 to 8 membered heterocycle, which may contain one or more additional heteroatoms selected from N, O, S, or P; or

R^7 taken together with L^2, and the N to which they are both attached, forms a substituted or unsubstituted 3 to 8 membered heterocycle which may contain one or more additional heteroatoms selected from N, O, S, or P; or

R^7 taken together with D^2, L^2, and the N to which both R^7 and L^2 are attached forms a substituted or unsubstitued 5 to 15 membered heterocycle or heteroaryl which may contain one or more additional heteroatoms selected from N, O, S, or P;

R^8 is H, alkyl, substituted alkyl, haloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclylalkyl, substituted heterocyclylalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylalkenyl, substituted carbocyclylalkenyl, carbocyclylalkynyl, substituted carbocyclylalkynyl, heterocyclylalkenyl, substituted heterocyclylalkenyl, heterocyclylalkynyl, substituted heteroalkynyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroarylalkenyl, substituted heteroarylalkenyl, heteroarylalkynyl, substituted heteroarylalkynyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl, heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl; and

R^9 and R^{10} are each independently H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, haloalkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted heterocyclylalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylalkenyl, substituted

carbocyclylalkenyl, carbocyclylalkynyl, substituted carbocyclylalkynyl, heterocyclylalkenyl, substituted heterocyclylalkenyl, heterocyclylalkynyl, substituted heterocyclylalkynyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroarylalkenyl, substituted heteroarylalkenyl, heteroarylalkynyl, substituted heteroarylalkynyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl, heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl; or

R^9 and R^{10}, taken together with the atom to which they are both attached, form a substituted or unsubstituted 3 to 8 membered heterocycle, which may contain one or more additional heteroatoms selected from N, O, S, or P.

2. A compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein:

L^1 is –NH- or –O-;

R^1 is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, carbocylyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclylalkyl, or substituted heterocycylalkyl;

X^1 is alkylene, substituted alkylene, heteroalkylene, or substituted heteroalkylene;

D^1 is aryl or heteroaryl;

D^2 is aryl or heteroaryl;

n is 0, 1, or 2;

each R^3 and R^4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, heteroalkyl, substituted heteroalkyl, =O, $-OR^8$, $-SR^8$, $-NR^9R^{10}$, $=NR^8$, $=NOR^8$, $=NNR^8R^9$, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, $-NO_2$, $=N_2$, $-N_3$, $-NR^8C(=O)R^9$, $-NR^8C(=O)OR^9$, $-NR^8C(=O)NR^9R^{10}$, $-C(=O)NR^9R^{10}$, $-C(=O)OR^8$, $-OC(=O)NR^9R^{10}$, $-OC(=O)OR^8$, $-C(=O)R^8$, $-S(=O)_2OR^8$, $-S(=O)_2R^8$, $-OS(=O)_2OR^8$, $-S(=O)_2NR^9R^{10}$, $-S(=O)R^8$, $-NR^8S(=O)_2R^9$, $-NR^8S(=O)_2NR^9R^{10}$, $-NR^8S(=O)_2OR^9$, $-OS(O)_2NR^9R^{10}$, $-OP(=O)(OR^8)_2$, $-P(=O)(OR^8)_2$, $-P(O)(OR^8)(R^9)$, $-P(O)R^9R^{10}$, $-OP(=))R^9R^{10}$, $-C(=S)R^8$, $-C(=S)OR^8$, $-C(=O)SR^8$, $-C(=S)SR^8$, $-C(=S)NR^9R^{10}$, $-C(=NR^8)NR^9R^{10}$, or $-NR^8C(=NR^8)NR^9R^{10}$;

m is 1 or 2;

L^2 is alkylene or heteroalkylene;

X^2 is N or C-R^5;

R^5 is H, halogen, alkyl, substituted alkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, cyano, azido, -C(O)H, $-C(O)R^8$, $-S(O)R^8$, $-S(O)_2R^8$, $-S(O)_2NR^8R^9$, $-C(O)OR^8$, or $-C(O)NR^9R^{10}$;

R^2 is $-NR^6R^7$; and

each of R^6 and R^7 independently is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, carbocylylalkyl, substituted carbocyclylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, or substituted heteroarylalkyl; or together with the nitrogen to which they are attached form a substituted or unsubstituted 3 to 8 membered heterocyclyl, which may contain one or more additional heteroatoms selected from N, O, S, or P; and

R^8, R^9, and R^{10} are each independently H, alkyl, substituted alkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted heterocyclylalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylalkenyl, substituted carbocyclylalkenyl, carbocyclylalkynyl, substituted carbocyclylalkynyl, heterocyclylalkenyl, substituted heterocyclylalkenyl, heterocyclylalkynyl, substituted heteroalkynyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroarylalkenyl, substituted heteroarylalkenyl, heteroarylalkynyl, substituted heteroarylalkynyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl, heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl.

3. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein:

L^1 is –NH- or –O-;

R^1 is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, carbocylyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclylalkyl, or substituted heterocycylalkyl;

X^1 is alkylene, substituted alkylene, heteroalkylene, or substituted heteroalkylene;

D^1 is aryl or heteroaryl;

D^2 is aryl or heteroaryl;

n is 0, 1, or 2;

each R^3 and R^4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, heteroalkyl, substituted heteroalkyl, =O, $-OR^8$, $-SR^8$, $-NR^9R^{10}$, $=NR^8$, $=NOR^8$, $=NNR^8R^9$, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, $-NO_2$, $=N_2$, $-N_3$, $-NR^8C(=O)R^9$, $-NR^8C(=O)OR^9$, -

$NR^8C(=O)NR^9R^{10}$, $-C(=O)NR^9R^{10}$, $-C(=O)OR^8$, $-OC(=O)NR^9R^{10}$, $-OC(=O)OR^8$, $-C(=O)R^8$, $-S(=O)_2OR^8$, $-S(=O)_2R^8$, $-OS(=O)_2OR^8$, $-S(=O)_2NR^9R^{10}$, $-S(=O)R^8$, $-NR^8S(=O)_2R^9$, $-NR^8S(=O)_2NR^9R^{10}$, $-NR^8S(=O)_2OR^9$, $-OS(O)_2NR^9R^{10}$, $-OP(=O)(OR^8)_2$, $-P(=O)(OR^8)_2$, $-P(O)(OR^8)(R^9)$, $-P(O)R^9R^{10}$, $-OP(=))R^9R^{10}$, $-C(=S)R^8$, $-C(=S)OR^8$, $-C(=O)SR^8$, $-C(=S)SR^8$, $-C(=S)NR^9R^{10}$, $-C(=NR^8)NR^9R^{10}$, or $-NR^8C(=NR^8)NR^9R^{10}$;

m is 1 or 2;

L^2 is alkylene or heteroalkylene;

X^2 is N or C-R^5;

R^5 is H, halogen, alkyl, substituted alkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, cyano, azido, -C(O)H, $-C(O)R^8$, $-S(O)R^8$, $-S(O)_2R^8$, $-S(O)_2NR^8R^9$, $-C(O)OR^8$, or $-C(O)NR^9R^{10}$;

R^2 is $-NR^6R^7$;

R^6 and R^7 together with the nitrogen to which they are attached form a substituted or unsubstituted 3 to 8 membered heterocyclyl, which may contain one or more additional heteroatoms selected from N, O, S, or P; and

R^8, R^9, and R^{10} are each independently H, alkyl, substituted alkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted heterocyclylalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylalkenyl, substituted carbocyclylalkenyl, carbocyclylalkynyl, substituted carbocyclylalkynyl, heterocyclylalkenyl, substituted heterocyclylalkenyl, heterocyclylalkynyl, substituted heterocyclylalkynyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroarylalkenyl, substituted heteroarylalkenyl, heteroarylalkynyl, substituted heteroarylalkynyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl, heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl.

4. A compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein:

L^1 is –NH- or –O-;

R^1 is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, carbocylyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclylalkyl, or substituted heterocycylalkyl;

X^1 is alkylene, substituted alkylene, heteroalkylene, or substituted heteroalkylene;

D^1 is aryl or heteroaryl;

D^2 is aryl or heteroaryl;

n is 0, 1, or 2;

each R^3 and R^4 is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, haloalkyl, haloalkoxy, heteroalkyl, substituted heteroalkyl, =O, $-OR^8$, $-SR^8$, $-NR^9R^{10}$, $=NR^8$, $=NOR^8$, $=NNR^8R^9$, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, $-NO_2$, $=N_2$, $-N_3$, $-NR^8C(=O)R^9$, $-NR^8C(=O)OR^9$, $-NR^8C(=O)NR^9R^{10}$, $-C(=O)NR^9R^{10}$, $-C(=O)OR^8$, $-OC(=O)NR^9R^{10}$, $-OC(=O)OR^8$, $-C(=O)R^8$, $-S(=O)_2OR^8$, $-S(=O)_2R^8$, $-OS(=O)_2OR^8$, $-S(=O)_2NR^9R^{10}$, $-S(=O)R^8$, $-NR^8S(=O)_2R^9$, $-NR^8S(=O)_2NR^9R^{10}$, $-NR^8S(=O)_2OR^9$, $-OS(O)_2NR^9R^{10}$, $-OP(=O)(OR^8)_2$, $-P(=O)(OR^8)_2$, $-P(O)(OR^8)(R^9)$, $-P(O)R^9R^{10}$, $-OP(=))R^9R^{10}$, $-C(=S)R^8$, $-C(=S)OR^8$, $-C(=O)SR^8$, $-C(=S)SR^8$, $-C(=S)NR^9R^{10}$, $-C(=NR^8)NR^9R^{10}$, or $-NR^8C(=NR^8)NR^9R^{10}$;

m is 1 or 2;

L^2 is alkylene or heteroalkylene;

X^2 is N or C-R^5;

R^5 is H, halogen, alkyl, substituted alkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, cyano, azido, -C(O)H, $-C(O)R^8$, $-S(O)R^8$, $-S(O)_2R^8$, $-S(O)_2NR^8R^9$, $-C(O)OR^8$, or $-C(O)NR^9R^{10}$;

R^2 is $-NR^6R^7$; and

R^6 is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, substituted heterocyclyl, carbocylylalkyl, substituted carbocyclylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, or substituted heteroarylalkyl; or together with R^7 and the nitrogen to which they are attached form a substituted or unsubstituted 3 to 8 membered heterocyclyl, which may contain one or more additional heteroatoms selected from N, O, S, or P; or

R^7 taken together with D^2, L^2, and the N to which both R^7 and L^2 are attached forms a substituted or unsubstitued 5 to 15 membered heterocycle or heteroaryl which may contain one or more additional heteroatoms selected from N, O, S, or P; and

R^8, R^9, and R^{10} are each independently H, alkyl, substituted alkyl, haloalkyl, heteroalkyl, substituted heteroalkyl, carbocyclyl, substituted carbocyclyl, carbocyclylalkyl, substituted carbocyclylalkyl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted heterocyclylalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, carbocyclylalkenyl, substituted carbocyclylalkenyl, carbocyclylalkynyl, substituted carbocyclylalkynyl,

heterocyclylalkenyl, substituted heterocyclylalkenyl, heterocyclylalkynyl, substituted heterocyclylalkynyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heteroarylalkenyl, substituted heteroarylalkenyl, heteroarylalkynyl, substituted heteroarylalkynyl, carbocyclylheteroalkyl, substituted carbocyclylheteroalkyl, heterocyclylheteroalkyl, substituted heterocyclylheteroalkyl, arylheteroalkyl, substituted arylheteroalkyl, heteroarylheteroalkyl, or substituted heteroarylheteroalkyl.

5. The compound of any one of claims 1 - 4, wherein X^2 is N.

6. The compound of any one of claims 1 - 5, wherein X^2 is C-R^5.

7. The compound of any one of claims 1 - 6, wherein L^1 is oxygen.

8. The compound of any one of claims 1 - 7, wherein X^1 is alkylene.

9. The compound of any one of claims 1 - 8, wherein D^1 is aryl.

10. The compound of claim 9, wherein D^1 is phenyl.

11. The compound of any one of claims 1 - 10, wherein D^2 is aryl.

12. The compound of any one of claims 1 - 11, wherein L^2 is alkylene.

13. A pharmaceutical composition comprising a compound according to Claims 1 – 12, and one or more pharmaceutically acceptable carrier or excipient.

14. The pharmaceutical composition of Claim 13, further comprising one or more additional therapeutic agent.

15. A method for treating a viral infection comprising administering a compound according to Claims 1 – 12.

16. The method of Claim 15, wherein the treatment results in one or more of a reduction in viral load or clearance of viral RNA.

17. Use of a compound according to Claims 1 – 12 for the manufacture of a medicament for the treatment of a viral infection.

18. A compound according to Claims 1 – 12 for the use in treating a viral infection.

19. The use or compound of Claim 17 or 18, wherein the treatment results in one or more of a reduction in viral load or clearance of viral RNA.

20. A method for treating or preventing melanoma, non-small cell lung carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, or influenza comprising administering a compound according to Claims 1 – 12.

21. Use of a compound according to Claims 1 – 12 for the manufacture of a medicament for the treatment or prevention of melanoma, non-small cell lung carcinoma, hepatocellular carcinoma, basal cell carcinoma, renal cell carcinoma, myeloma, allergic rhinitis, asthma, COPD, ulcerative colitis, hepatic fibrosis, HBV, HCV, HPV, RSV, SARS, HIV, or influenza.